Abstract
This review covers two major strategies for imaging of the brain cannabinoid system: autoradiography and in vivo neuroimaging. Cannabinoid receptors can be imaged directly with autoradiography in brain slices using radiolabeled cannabinoid receptor ligands. In addition, the effects of pharmacologic doses of unlabeled cannabinoid drugs can be autoradiographically imaged using indicators of blood flow or indicators of metabolism such as glucose analogs. Although cannabinoid imaging is a relatively new topic of research compared to imaging of other drugs of abuse, autoradiographic strategies have produced high-quality information about the distribution of brain cannabinoid receptors and the effects of cannabinoid drugs on brain metabolism. In vivo neuroimaging, in contrast to autoradiography, utilizes noninvasive techniques such as positron emission tomography (PET), single photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI) to image both the binding and the effects of drugs within living brain. These techniques are well developed; however, in vivo imaging of cannabinoid systems is in a very preliminary state. Early results have been promising yet hard to generalize. Definitive answers to some of the most important questions about cannabinoid drugs and their effects await development of suitable in vivo neuroimaging ligands for cannabinoid systems.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adams IB, Compton DR, Martin BR (1998) Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209–1217
Arseneault L, Cannon M, Witton J, Murray RM (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184:110–117
Berding G, Muller-Vahl K, Schneider U, Gielow P, Fitschen J, Stuhrmann M, Harke H, Buchert R, Donnerstag F, Hofmann M, Knoop BO, Brooks DJ, Emrich HM, Knapp WH (2004). [(123)I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB(1) receptors before and after Delta(9)-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. Biol Psychiatry. 55:904–915
Biegon A, Kerman IA (2001) Autoradiographic study of pre-and postnatal distribution of cannabinoid receptors in human brain. Neuroimage 14:1463–1468
Block RI, O’Leary DS, Ehrhardt JC, Augustinack JC, Ghoneim MM, Arndt S, Hall JA (2000a) Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport 11:491–496
Block RI, O’Leary DS, Hichwa RD, Augustinack JC, Ponto LL, Ghoneim MM, Arndt S, Ehrhardt JC, Hurtig RR, Watkins GL, Hall JA, Nathan PE, Andreasen NC (2000b) Cerebellar hypoactivity in frequent marijuana users. Neuroreport 11:749–753
Block RI, O’Leary DS, Hichwa RD, Augustinack JC, Boles Ponto LL, Ghoneim MM, Arndt S, Hurtig RR, Watkins GL, Hall JA, Nathan PE, Andreasen NC (2002) Effects of frequent marijuana use on memory-related regional cerebral blood flow. Pharmacol Biochem Behav 72:237–250
Bloom AS, Tershner S, Fuller SA, Stein EA (1997) Cannabinoid-induced alterations in regional cerebral blood flow in the rat. Pharmacol Biochem Behav 57:625–631
Brett R, MacKenzie F, Pratt J (2001) Delta 9-tetrahydrocannabinol-induced alterations in limbic system glucose use in the rat. Neuroreport 12:3573–3577
Calignano A, La Rana G, Giuffrida A, Piomelli D (1998) Control of pain initiation by endogenous cannabinoids. Nature 394:277–281
Campbell AM, Evans M, Thomson JL, Williams MJ (1971) Cerebral atrophy in young cannabis smokers. Lancet 2:1219–1224
Chang L, Leckova K, Cloak C, Arnold S, Yakupov R, Lozar C, Warren K, Ernst T (2003) Decreased BOLD activation during visual attention tasks in marijuana abusers. International Society of Magnetic Resonance in Medicine. Toronto, ON, Canada
Charalambous A, Marciniak G, Shiue CY, Dewey SL, Schlyer DJ, Wolf AP, Makriyannis A (1991) PET studies in the primate brain and biodistribution in mice using (-)-5’-18F-delta 8-THC. Pharmacol Biochem Behav 40:503–507
Co BT, Goodwin DW, Gado M, Mikhael M, Hill SY (1977) Absence of cerebral atrophy in chronic cannabis users. Evaluation by computerized transaxial tomography. JAMA 237:1229–1230
Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR (1992a) Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 263:1118–1126
Compton DR, Johnson MR, Melvin LS, Martin BR (1992b) Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 260:201–209
Dean B, Sundram S, Bradbury R, Scarr E, Copolov D (2001) Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103:9–15
Dewey SL, Smith GS, Logan J, Brodie JD, Fowler JS, Wolf AP (1993b) Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13:350–356
Di Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM, Zimmer A, Martin BR (2000) Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor mediated actions of anandamide in mouse brain. J Neurochem 75:2434–2444
Freedland CS, Whitlow CT, Miller MD, Porrino LJ (2002) Dose-dependent effects of delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat. Synapse 45:134–142
Freedland CS, Whitlow CT, Smith HR, Porrino LJ (2003) Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR 141716A, in cannabinoid-naive and-tolerant animals: a quantitative 2-[14C]deoxyglucose study. Brain Res 962:169–179
Gatley SJ (1996) Positron radiopharmaceutical agents and their chemistry. In: Henkin RE, Boles MA, Dillehay GL, Halama JR, Karesh SM, Wagner RH, Zimmer AM (eds) Nuclear medicine. Mosby, St Louis, pp 429–444
Gatley SJ (2003) Labeled glucose analogs in the genomic era. J Nucl Med 44:1082–1086
Gatley SJ, Volkow ND (1998) Addiction and imaging of the living human brain. Drug Alcohol Depend 51:97–108
Gatley SJ, Lan R, Volkow ND, Pappas N, King P, Wong CT, Gifford AN, Pyatt B, Dewey SL, Makriyannis A (1998) Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem 70:417–423
Gatley SJ, Gifford AN, Ding YS, Lan R, Liu Q, Volkow ND, Makriyannis A (2004) Development of PET and SPECT radioligands for cannabinoid receptors. In: Makriyannis A, Biegel D, Dekker M (eds) Drug discovery strategies and methods. Marcel Dekker, New York, pp 129–146
Gifford AN, Makriyannis A, Volkow ND, Gatley SJ (2002) In vivo imaging of the brain cannabinoid receptor. Chem Phys Lipids 121:65–72
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87:1932–1936
Iyo M, Namba H, Yanagisawa M, Hirai S, Yui N, Fukui S (1997) Abnormal cerebral perfusion in chronic methamphetamine abusers: a study using 99MTc-HMPAO and SPECT. Prog Neuropsychopharmacol Biol Psychiatry 21:789–796
Jacobsen LK, Mencl WE, Westerveld M, Pughz KR (2004). Impact of cannabis use on brain function in adolescents. Ann N Y Acad Sci. 1021:384–390
Katoch-Rouse R, Pavlova OA, Caulder T, Hoffman AF, Mukhin AG, Horti AG (2003) Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity. J Med Chem 46:642–645
Kuehnle J, Mendelson JH, Davis KR, New PF (1977) Computed tomographic examination of heavy marijuana smokers. JAMA 237:1231–1232
Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423–451
Margulies JE, Hammer RP Jr (1991) Delta 9-tetrahydrocannabinol alters cerebral metabolis in a biphasic, dose-dependent manner in rat brain. Eur J Pharmacol 202:373–378
Mathew RJ, Wilson WH, Humphreys DF, Lowe JV, Wiethe KE (1992) Regional cerebral blood flow after marijuana smoking. J Cereb Blood Flow Metab 12:750–758
Mathew RJ, Wilson WH, Coleman RE, Turkington TG, DeGrado TR (1997) Marijuana intoxication and brain activation in marijuana smokers. Life Sci 60:2075–2089
Mathew RJ, Wilson WH, Turkington TG, Coleman RE (1998) Cerebellar activity and disturbed time sense after THC. Brain Res 797:183–189
Mathew RJ, Wilson WH, Chiu NY, Turkington TG, Degrado TR, Coleman RE (1999) Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration. Acta Psychiatr Scand 100:67–75
Mathew RJ, Wilson WH, Turkington TG, Hawk TC, Coleman RE, DeGrado TR, Provenzale J (2002) Time course of tetrahydrocannabinol-induced changes in regional cerebral blood flow measured with positron emission tomography. Psychiatry Res 116:173–185
Mathews WB, Scheffel U, Finley P, Ravert HT, Frank RA, Rinaldi-Carmona M, Barth F, Dannals RF (2000) Biodistribution of [18F] SR144385 and [18F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors. Nucl Med Biol 27:757–762
Mathews WB, Scheffel U, Rauseo PA, Ravert HT, Frank RA, Ellames GJ, Herbert JM, Barth F, Rinaldi-Carmona M, Dannals RF (2002) Carbon-11 labeled radioligands for imaging brain cannabinoid receptors. Nucl Med Biol 29:671–677
O’Leary DS, Block RI, Flaum M, Schultz SK, Boles Ponto LL, Watkins GL, Hurtig RR, Andreasen NC, Hichwa RD (2000) Acute marijuana effects on rCBF and cognition: a PET study. Neuroreport 11:3835–3841
O’Leary DS, Block RI, Koeppel JA, Flaum M, Schultz SK, Andreasen NC, Ponto LB, Watkins GL, Hurtig RR, Hichwa RD (2002) Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 26:802–816
O’Leary DS, Block RI, Turner BM, Koeppel J, Magnotta VA, Ponto LB, Watkins GL, Hichwa RD, Andreasen NC (2003) Marijuana alters the human cerebellar clock. Neuroreport 14:1145–1151
Oviedo A, Glowa J, Herkenham M (1993) Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 616:293–302
Phelps ME (1991) PET: a biological imaging technique. Neurochem Res 16:929–940
Pontieri FE, Conti G, Zocchi A, Fieschi C, Orzi F (1999) Metabolic mapping of the effects of WIN 55212-2 intravenous administration in the rat. Neuropsychopharmacology 21:773–776
Porrino LJ (1993) Functional consequences of acute cocaine treatment depend on route of administration. Psychopharmacology (Berl) 112:343–351
Raichle ME, Martin WR, Herscovitch P, Mintun MA, Markham J (1983) Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation. J Nucl Med 24:790–798
Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, Casella V, Fowler J, Gallagher B, Hoffman E, Alavi A, Sokoloff L (1977) Measurement of local cerebral glucose metabolism in man with 18F-2-fluoro-2-deoxy-d-glucose. Acta Neurol Scand Suppl 64:190–191
Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, et al (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240–244
Rogers A (1973) Techniques of autoradiography, 2nd edn. Elsevier Scientific Publishing Company, Amsterdam
Romero J, Garcia-Palomero E, Castro JG, Garcia-Gil L, Ramos JA, Fernandez-Ruiz JJ (1997) Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res Mol Brain Res 46:100–108
Romero J, Berrendero F, Manzanares J, Perez A, Corchero J, Fuentes JA, Fernandez-Ruiz JJ, Ramos JA (1998) Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 30:298–308
Rubino T, Vigano D, Massi P, Spinello M, Zagato E, Giagnoni G, Parolaro D (2000) Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology 39:1331–1336
Sakurada O, Kennedy C, Jehle J, Brown JD, Carbin GL, Sokoloff L (1978) Measurement of local cerebral blood flow with iodo [14C] antipyrine. Am J Physiol 234:H59–66
Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, Chambers JK, Randall AD, Davis JB (2000) The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129:227–230
Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M (1977) The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897–916
Stein EA, Fuller SA, Edgemond WS, Campbell WB (1998) Selective effects of the endogenous cannabinoid arachidonylethanolamide (anandamide) on regional cerebral blood flow in the rat. Neuropsychopharmacology 19:481–491
Thomas BF, Wei X, Martin BR (1992) Characterization and autoradiographic localization of the cannabinoid binding site in rat brain using [3H]11-OH-delta 9-THC-DMH. J Pharmacol Exp Ther 263:1383–1390
Varma VK, Malhotra AK, Dang R, Das K, Nehra R (1988) Cannabis and cognitive functions: a prospective study. Drug Alcohol Depend 21:147–152
Volkow ND, Gillespie H, Mullani N, Tancredi L, Grant C, Ivanovic M, Hollister L (1991) Cerebellar metabolic activation by delta-9-tetrahydro-cannabinol in human brain: a study with positron emission tomography and 18F-2-fluoro-2-deoxyglucose. Psychiatry Res 40:69–78
Volkow ND, Gillespie H, Mullani N, Tancredi L, Grant C, Valentine A, Hollister L (1996) Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Res 67:29–38
Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG (2001) Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res 107:173-177
Whitlow CT, Freedland CS, Porrino LJ (2002) Metabolic mapping of the time-dependent effects of delta 9-tetrahydrocannabinol administration in the rat. Psychopharmacology (Berl) 161:129–136
Whitlow CT, Freedland CS, Porrino LJ (2003) Functional consequences of the repeated administration of Delta9-tetrahydrocannabinol in the rat. Drug Alcohol Depend 71:169–177
Wilson W, Mathew R, Turkington T, Hawk T, Coleman RE, Provenzale J (2000) Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J Addict Dis 19:1–22
Zavitsanou K, Garrick T, Huang XF (2004) Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:355–360
Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452–457
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Verlag
About this chapter
Cite this chapter
Lindsey, K.P., Glaser, S.T., Gatley, S.J. (2005). Imaging of the Brain Cannabinoid System. In: Pertwee, R.G. (eds) Cannabinoids. Handbook of Experimental Pharmacology, vol 168. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26573-2_14
Download citation
DOI: https://doi.org/10.1007/3-540-26573-2_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-22565-2
Online ISBN: 978-3-540-26573-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)